Risks of ABO Non-identical Plasma:Cognitive and Clinical Practice

doi:10.3969/j.issn.1671-2587.2024.02.003

JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE ›› 2024, Vol. 26 ›› Issue (2): 164-172.DOI: 10.3969/j.issn.1671-2587.2024.02.003

Previous Articles Next Articles

Risks of ABO Non-identical Plasma:Cognitive and Clinical Practice

ZHANG Leiying, YU Yang

Department of Transfusion Medicine, the First Medical Center of Chinese PLA General Hospital, Beijing 100853

Received:2024-02-04 Online:2024-04-20 Published:2024-04-23

Abstract

Abstract: Plasma transfusion is clinically used to replenish clotting factors and correct coagulopathy, playing an important role in the treatment of massive hemorrhage. Universal plasma and low titer group O whole blood can improve the timeliness and accessibility of urgent transfusions in patients with major bleeding. The strategy of ABO non-identical plasma transfusion, in the form of active and passive transfusion, has been extensively adopted in clinical practice. Active transfusion mainly includes group AB and A plasma; passive transfusion, on the other hand, involves the transfusion of low titer group O whole blood and ABO non-identical platelets. However, hemolysis and circulating immune complex formation are recognized to be the risks associated with transfusion of ABO non-identical plasma. Together, the risk-benefit trade-off with transfusion of non-ABO identical plasma deserves more attention and further exploration.

Key words: ABO non-identical, ABO-Incompatible, Plasma, Whole blood, Platelet, Risk

CLC Number:

R457

ZHANG Leiying, YU Yang. Risks of ABO Non-identical Plasma:Cognitive and Clinical Practice[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(2): 164-172.

References

[1] HOLCOMB J B,DEL JUNCO D J,FOX E E,et al.The prospective,observational,multicenter,major trauma transfusion (PROMMTT) study:comparative effectiveness of a time-varying treatment with competing risks[J].JAMA Surg,2013,148(2):127-136.
[2] 中华人民共和国卫生部.临床输血技术规范[S].2000.
[3] 国家卫生健康委员会.全血和成分血使用[S].2018.
[4] Claudia S.Cohn.AABB technical manual(20th edition)[M].Bethesda,MD:AABB Press, 2020.
[5] STANWORTH S J,DOWLING K,CURRY N,et al.Haematological management of major haemorrhage:a British Society for Haematology Guideline[J].Br J Haematol,2022,198(4):654-667.
[6] ZIELINSKI M D,SCHRAGER J J,JOHNSON P,et al.Multicenter comparison of emergency release group A versus AB plasma in blunt-injured trauma patients[J].Clin Transl Sci,2015,8(1):43-47.
[7] HOLCOMB J B,JENKINS D,RHEE P,et al.Damage control resuscitation:directly addressing the early coagulopathy of trauma[J].J Trauma,2007,62(2):307-310.
[8] STEVENS W T,MORSE B C,BERNARD A,et al.Incompatible type A plasma transfusion in patients requiring massive transfusion protocol:outcomes of an Eastern Association for the Surgery of Trauma multicenter study[J].J Trauma Acute Care Surg,2017,83(1):25-29.
[9] ZIELINSKI M D,JOHNSON P M,JENKINS D,et al.Emergency use of prethawed Group A plasma in trauma patients[J].J Trauma Acute Care Surg,2013,74(1):69-74;discussion 74-75.
[10] CHHIBBER V,GREENE M,VAUTHRIN M,et al.Is group A thawed plasma suitable as the first option for emergency release transfusion? (CME)[J].Transfusion,2014,54(7):1751-1755;quiz 1750.
[11] SEHEULT J N,BAHR M,ANTO V,et al.Safety profile of uncrossmatched,cold-stored,low-titer,group O+ whole blood in civilian trauma patients[J].Transfusion,2018,58(10):2280-2288.
[12] SILETZ A E,BLAIR K J,COOPER R J,et al.A pilot study of stored low titer group O whole blood + component therapy versus component therapy only for civilian trauma patients[J].J Trauma Acute Care Surg,2021,91(4):655-662.
[13] TROUGHTON M,YOUNG P P.Conservation of Rh negative Low Titer O Whole Blood (LTOWB) and the need for a national conversation to define its use in trauma transfusion protocols[J].Transfusion,2021,61(6):1966-1971.
[14] YAZER M H,CAP A P,SPINELLA P C.Raising the standards on whole blood[J].J Trauma Acute Care Surg,2018,84(6S Suppl 1):S14-S17.
[15] DUNBAR N M,KATUS M C,FREEMAN C M,et al.Easier said than done:ABO compatibility and D matching in apheresis platelet transfusions[J].Transfusion,2015,55(8):1882-1888.
[16] SOLVES P,CARPIO N,BALAGUER A,et al.Transfusion of ABO non-identical platelets does not influence the clinical outcome of patients undergoing autologous haematopoietic stem cell transplantation[J].Blood Transfus,2015,13(3):411-416.
[17] HOLCOMB J B,PATI S.Optimal trauma resuscitation with plasma as the primary resuscitative fluid:the surgeon's perspective[J].Hematology Am Soc Hematol Educ Program,2013,2013:656-659.
[18] PATI S,POTTER D R,BAIMUKANOVA G,et al.Modulating the endotheliopathy of trauma:factor concentrate versus fresh frozen plasma[J].J Trauma Acute Care Surg,2016,80(4):576-584;discussion 584-585.
[19] PENG Z L,PATI S,POTTER D,et al.Fresh frozen plasma lessens pulmonary endothelial inflammation and hyperpermeability after hemorrhagic shock and is associated with loss of syndecan 1[J].Shock,2013,40(3):195-202.
[20] SPERRY J L,GUYETTE F X,BROWN J B,et al.Prehospital plasma during air medical transport in trauma patients at risk for hemorrhagic shock[J].N Engl J Med,2018,379(4):315-326.
[21] DE BIASI A R,STANSBURY L G,DUTTON R P,et al.Blood product use in trauma resuscitation:plasma deficit versus plasma ratio as predictors of mortality in trauma (CME)[J].Transfusion,2011,51(9):1925-1932.
[22] DEL JUNCO D J,HOLCOMB J B,FOX E E,et al.Resuscitate early with plasma and platelets or balance blood products gradually:findings from the PROMMTT study[J].J Trauma Acute Care Surg,2013,75(1 Suppl 1):S24-S30.
[23] HOLCOMB J B,TILLEY B C,BARANIUK S,et al.Transfusion of plasma,platelets,and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma:the PROPPR randomized clinical trial[J].JAMA,2015,313(5):471-482.
[24] YAZER M,EDER A F,LAND K J.How we manage AB plasma inventory in the blood center and transfusion service[J].Transfusion,2013,53(8):1627-1633.
[25] BORGMAN M A,SPINELLA P C,PERKINS J G,et al.The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital[J].J Trauma,2007,63(4):805-813.
[26] GARRATTY G,GLYNN S A,MCENTIRE R,et al.ABO and Rh(D) phenotype frequencies of different racial/ethnic groups in the United States[J].Transfusion,2004,44(5):703-706.
[27] SUN Y,WANG L Q,NIU J M,et al.Distribution characteristics of ABO blood groups in China[J].Heliyon,2022,8(9):e10568.
[28] MALKIN M,NEVO A,BRUNDAGE S I,et al.Effectiveness and safety of whole blood compared to balanced blood components in resuscitation of hemorrhaging trauma patients - A systematic review[J].Injury,2021,52(2):182-188.
[29] SHEA S M,STAUDT A M,THOMAS K A,et al.The use of low-titer group O whole blood is independently associated with improved survival compared to component therapy in adults with severe traumatic hemorrhage[J].Transfusion,2020,60(Suppl 3):S2-S9.
[30] JR B A.Status of the use of universal donor blood transfusion[J].CRC Crit Rev Clin Lab Sci,1973,4(2):147-160.
[31] BARNES A.Transfusion of universal donor and uncrossmatched blood[J].Bibl Haematol,1980(46):132-142.
[32] BALLAS M,NORDSTROM E.Severe hemolysis following the transfusion of one unit of O negative blood[J].USARV Med Bull,1968,40:50-51.
[33] CROSBY W H,AKEROYD J H.Some immunohematologic results of large transfusions of group O blood in recipients of other blood groups;a study of battle casualties in Korea[J].Blood,1954,9(2):103-116.
[34] BAHR M P,YAZER M H,TRIULZI D J,et al.Whole blood for the acutely haemorrhaging civilian trauma patient:a novel idea or rediscovery?[J].Transfus Med,2016,26(6):406-414.
[35] CORDOVA C B,CAP A P,SPINELLA P C.Fresh whole blood transfusion for a combat casualty in austere combat environment[J].J Spec Oper Med,2014,14(1):9-12.
[36] SPINELLA P C,PERKINS J G,GRATHWOHL K W,et al.Fresh whole blood transfusions in coalition military,foreign national,and enemy combatant patients during Operation Iraqi Freedom at a U.S.combat support hospital[J].World J Surg,2008,32(1):2-6.
[37] YAZER M H,JACKSON B,SPERRY J L,et al.Initial safety and feasibility of cold-stored uncrossmatched whole blood transfusion in civilian trauma patients[J].J Trauma Acute Care Surg,2016,81(1):21-26.
[38] HENRICHS K F,HOWK N,MASEL D S,et al.Providing ABO-identical platelets and cryoprecipitate to (almost) all patients:approach,logistics,and associated decreases in transfusion reaction and red blood cell alloimmunization incidence[J].Transfusion,2012,52(3):635-640.
[39] 傅启华,王静.紧急抢救时ABO血型不相同血小板输注专家共识[J].中国输血杂志,2017,30(7):666-667.
[40] PIERSKALLA W P,ROACH C D.Optimal issuing policies for perishable inventory[J].Manag Sci,1972,18(11):603-614.
[41] 王鸿捷,郭永建.英国输血延误和美国血液紧缺监测概况与启示[J].中国输血杂志,2023,36(12):1171-1176.
[42] Food and Drug Administration Center for Biologics Evaluation and Research Document Control Center.Transfusion/Donation Fatalities:Fatalities Reported to FDA Following Blood Collection and Transfusion Annual Summary for Fiscal Year2016-2021[J/OL].[2024-02-20].https://www.fda.gov/vaccines-blood-biologics/report-problem-center-biologics-evaluation-research/transfusiondonation-fatalities.
[43] RUBY K N,HARM S K,DUNBAR N M.Risk of ABO-incompatible plasma from non-ABO-identical components[J].Transfus Med Rev,2021,35(4):118-122.
[44] MCCULLAGH J,CARDIGAN R,BRUNSKILL S J,et al.Assessing the risks of haemolysis as an adverse reaction following the transfusion of ABO incompatible plasma-containing components - A scoping review[J].Blood Rev,2022,56:100989.
[45] BERSÉUS O,BOMAN K,NESSEN S C,et al.Risks of hemolysis due to anti-A and anti-B caused by the transfusion of blood or blood components containing ABO-incompatible plasma[J].Transfusion,2013,53(Suppl 1):114S-123S.
[46] BELIN T R,YAZER M H,MELEDEO M A,et al.An evaluation of methods for producing low-titer group O whole blood to support military trauma resuscitation[J].J Trauma Acute Care Surg,2017,82(6S Suppl 1):S79-S86.
[47] YAZER M H,SPINELLA P C.An international survey on the use of low titer group O whole blood for the resuscitation of civilian trauma patients in 2020[J].Transfusion,2020,60(Suppl 3):S176-S179.
[48] 钱宝华,顾海慧,查占山.创伤紧急救治通用型红细胞输注专家共识[J].中国输血杂志,2017,30(7):668-669.
[49] 顾海慧,李津杞,葛立华,等.创伤紧急救治通用型红细胞输注的应用实施及效果评价[J].中国输血杂志,2019,32(9):893-897.
[50] 肖瑞卿,赵树铭,林武存,等.A、B、AB型全血加入O型全血37℃对血型鉴定、抗体效价及抗球蛋白试验的影响[J].第三军医大学学报,2005(18):1885-1887.
[51] 王培华. 输血技术学[M].第2版.北京:人民卫生出版社,2002.
[52] DUNBAR N M,YAZER M H,BIOMEDICAL Excellence for Safer Transfusion Collaborative.A possible new paradigm? A survey-based assessment of the use of thawed group A plasma for trauma resuscitation in the United States[J].Transfusion,2016,56(1):125-129.
[53] YAZER M H,SPINELLA P C,ANTO V,et al.Survey of group A plasma and low-titer group O whole blood use in trauma resuscitation at adult civilian level 1 trauma centers in the US[J].Transfusion,2021,61(6):1757-1763.
[54] DUNBAR N M,YAZER M H,BIOMEDICAL EXCELLENCE FOR SAFER TRANSFUSION (BEST) COLLABORATIVE AND THE STAT STUDY INVESTIGATORS.Safety of the use of group A plasma in trauma:the STAT study[J].Transfusion,2017,57(8):1879-1884.
[55] OLSEN G,PASSWATER M,HUGGINS M,et al.Evaluation of A plasma for incompatible patients[J].Transfusion,2021,61(2):375-378.
[56] EBERT R V,JR EMERSON C P.A clinical study of transfusion reactions:the hemolytic effect of group-o blood and pooled plasma containing incompatible isoagglutinins[J].J Clin Invest,1946,25(4):627-638.
[57] SEHEULT J N,TRIULZI D J,ALARCON L H,et al.Measurement of haemolysis markers following transfusion of uncrossmatched,low-titre,group O+ whole blood in civilian trauma patients:initial experience at a level 1 trauma centre[J].Transfus Med,2017,27(1):30-35.
[58] HARROLD I M,SEHEULT J N,ALARCON L H,et al.Hemolytic markers following the transfusion of uncrossmatched,cold-stored,low-titer,group O+ whole blood in civilian trauma patients[J].Transfusion,2020,60(Suppl 3):S24-S30.
[59] WILLIAMS J,MERUTKA N,MEYER D,et al.Safety profile and impact of low-titer group O whole blood for emergency use in trauma[J].J Trauma Acute Care Surg,2020,88(1):87-93.
[60] CURTIS B R,EDWARDS J T,HESSNER M J,et al.Blood group A and B antigens are strongly expressed on platelets of some individuals[J].Blood,2000,96(4):1574-1581.
[61] QUILLEN K,SHELDON S L,DANIEL-JOHNSON J A,et al.A practical strategy to reduce the risk of passive hemolysis by screening plateletpheresis donors for high-titer ABO antibodies[J].Transfusion,2011,51(1):92-96.
[62] MAIR B,BENSON K.Evaluation of changes in hemoglobin levels associated with ABO-incompatible plasma in apheresis platelets[J].Transfusion,1998,38(1):51-55.
[63] FUNG M K,DOWNES K A,SHULMAN I A.Transfusion of platelets containing ABO-incompatible plasma:a survey of 3156 North American laboratories[J].Arch Pathol Lab Med,2007,131(6):909-916.
[64] MOINUDDIN I A,MILLWARD P,FLETCHER C H.Acute intravascular hemolysis following an ABO non-identical platelet transfusion:a case report and literature review[J].Am J Case Rep,2019,20:1075-1079.
[65] FONTAINE M J,MILLS A M,WEISS S,et al.How we treat:risk mitigation for ABO-incompatible plasma in plateletpheresis products[J].Transfusion,2012,52(10):2081-2085.
[66] Transfusion of apheresis platelets and ABO groups[J].Vox Sang,2005,88(3):207-221.
[67] KARAFIN M S,BLAGG L,TOBIAN A A R,et al.ABO antibody titers are not predictive of hemolytic reactions due to plasma-incompatible platelet transfusions[J].Transfusion,2012,52(10):2087-2093.
[68] ACHERMANN F J,JULMY F,GILLIVER L G,et al.Soluble type A substance in fresh-frozen plasma as a function of ABO and Secretor genotypes and Lewis phenotype[J].Transfus Apher Sci,2005,32(3):255-262.
[69] HEGER A,BRANDSTÄTTER H,PRAGER B,et al.Universal pooled plasma (Uniplas(®)) does not induce complement-mediated hemolysis of human red blood cells in vitro[J].Transfus Apher Sci,2015,52(1):128-135.
[70] INABA K,BRANCO B C,RHEE P,et al.Impact of ABO-identical vs ABO-compatible nonidentical plasma transfusion in trauma patients[J].Arch Surg,2010,145(9):899-906.
[71] SHANWELL A,ANDERSSON T M,ROSTGAARD K,et al.Post-transfusion mortality among recipients of ABO-compatible but non-identical plasma[J].Vox Sang,2009,96(4):316-323.
[72] MACLEOD J B A,LYNN M,MCKENNEY M G,et al.Early coagulopathy predicts mortality in trauma[J].J Trauma,2003,55(1):39-44.
[73] LEWIS M,SHULMAN I,HUDGINS J,et al.Essentials of emergency transfusion-The complement to stop the bleed[J].J Trauma Acute Care Surg,2019,87(2):420-429.
[74] MEYER D E,VINCENT L E,FOX E E,et al.Every minute counts:time to delivery of initial massive transfusion cooler and its impact on mortality[J].J Trauma Acute Care Surg,2017,83(1):19-24.
[75] 陈翔宇,刘红升,向强,等.创伤失血性休克中国急诊专家共识(2023)[J].临床急诊杂志,2023,24(12):609-623.
[76] KOTWAL R S,HOWARD J T,ORMAN J A,et al.The effect of a golden hour policy on the morbidity and mortality of combat casualties[J].JAMA Surg,2016,151(1):15-24.
[77] TRIULZI D J,ASSMANN S F,STRAUSS R G,et al.The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia[J].Blood,2012,119(23):5553-5562.
[78] PAVENSKI K,WARKENTIN T E,SHEN H,et al.Posttransfusion platelet count increments after ABO-compatible versus ABO-incompatible platelet transfusions in noncancer patients:an observational study[J].Transfusion,2010,50(7):1552-1560.

Risks of ABO Non-identical Plasma:Cognitive and Clinical Practice

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

About

Author

Journal

Access Statistics

Contact

[1]	Chinese Blood Transfusion Association Clinical Transfusion Management Committee. Chinese Expert Consensus on Preoperative Advanced Autologous Apheresis [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(2): 145-155.
[2]	LIU Ruining, WANG Deqing. Current Realities and Novel Improvements of Plasma Transfusion [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(2): 180-186.
[3]	CHEN Xin, SHAO Xiaobao, XUE Changwen, ZHOU Lin, ZHU Peiyuan. Experimental Study on Inhibition of the Interaction between Platelets and Tumor Cells by Tanshinone ⅡA [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(2): 187-195.
[4]	XIE Huihan, SHAO Xiaobao, CHEN Xin, ZHOU Lin, ZHU Peiyuan. Characterization of Salidroside for the Preservation of Apheresis Platelets [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(2): 196-204.
[5]	XUE Changwen, SHAO Xiaobao, CHEN Xin, ZHOU Lin, ZHU Peiyuan. Experimental Study on Inhibition of Interaction between Platelets and Tumor Cells by Ginkgolide B [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(2): 205-212.
[6]	YAN Meiling, ZHU Peiyuan. Exploring the Mechanism of Action of Taohongsiwu Decoction on Platelet Activation Based on Network Pharmacology and Molecular Docking [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(2): 213-222.
[7]	GE Xiaoqin, FU Heng, HU Guanlin, et al. Analysis of the Influence of the Outbreak of COVID-19 on the Blood Supply of Whole Blood Preparation Components in 25 Central Blood Stations in China [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(2): 244-250.
[8]	SHANG Wei, WANG Deqing. The Development Fibrinogen in the Treatment of Massive Traumatic Hemorrhage [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(2): 274-281.
[9]	YANG Xuexin, WEI Yaming. The Current Situation and Suggestions of ABO-mismatched Platelet Transfusions [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(1): 17-22.
[10]	YANG Xuexin, YUAN Yongmei, WU Zhaoyong, YUAN Zhaohu, LIU Zhen, TONG Xinxin, CHEN Xiaowei, WEI Yaming. The Preliminary Analysis of the Effectiveness and Safety of Minor ABO Incompatible Platelet Transfusions [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(1): 42-48.
[11]	DIAO Yujie, ZHU Bangqiang, WEN Huiqin, WANG Haijing, HU Yan, CHENG Yue, BIAN Maohong. Efficacy and Safety of Double Filtration Plasmapheresis to Remove High PRA Antibody before Kidney Transplantation [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(1): 49-54.
[12]	ZHANG Chengxin, YANG Jie, HAO Xinxin, WANG Qiushi. Determinants Affecting Hematopoietic Stem Cell Harvesting Efficacy: A Single-Center, Retrospective Cohort Study [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(1): 55-59.
[13]	REN Li, LI Xiaoli, XIAO Song, LI Xiaofei, LIU Zhizhong. Application of Serial Dilution with AB Plasma in Antibody Screening for Patients with High Titer Autoantibodies [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(1): 66-71.
[14]	ZHAO Xingdan, WENG Aihan. Influence Factors and A Prediction Model of Blood Transfusion and Transfusion Amount for Very Low Birth Weight Infants [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(6): 758-766.
[15]	LI Li, LIU Xiaoqing, SUN Yuai, et al. Analysis of the Influence of Different Calcium Supplementation Methods on Blood Ca²⁺ and PTH in Fixed Blood Donors [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(6): 798-801.